8-K: RenovoRx to Present Pancreatic Cancer Tech at KOL Webinar

RenovoRx announced its participation in a key opinion leader webinar discussing pancreatic cancer and its TAMP platform, scheduled for August 13, 2026.

Summary

• RenovoRx, Inc. will participate in a JonesTrading webinar on August 13, 2026, focusing on the evolving pancreatic cancer landscape.
• The webinar will feature Key Opinion Leaders (KOLs) in oncology and RenovoRx CEO Shaun Bagai.
• Discussions will cover RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) platform, enabled by the RenovoCath device, for local drug delivery.
• The ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine via RenovoCath for locally advanced pancreatic cancer will be a key topic.
• Commercial aspects, including RenovoCath sales and customer growth, will also be discussed.
• RenovoCath is FDA-cleared for specific peripheral vascular system applications, including chemotherapeutic drug infusion.
• RenovoRx reported approximately $1.1 million in RenovoCath sales for 2025 and $563,000 in Q1 2026.
• The company anticipates full enrollment in the TIGeR-PaC trial soon, with data readout expected mid to late 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, highlighting ongoing clinical trial progress and commercialization efforts, with a clear focus on a significant unmet medical need.

Positives

• Announcement of participation in a key opinion leader webinar to discuss the company's technology and its application in pancreatic cancer.
• Focus on the TAMP platform and RenovoCath device, highlighting their potential for targeted drug delivery.
• Inclusion of the ongoing Phase III TIGeR-PaC clinical trial, which is a critical step for potential drug approval.
• Commercial progress with RenovoCath, showing increasing revenues ($1.1 million in 2025, $563,000 in Q1 2026).
• Orphan Drug Designation for gemcitabine delivered via RenovoCath for pancreatic cancer, providing potential market exclusivity.
• Anticipation of near-term full enrollment in the TIGeR-PaC trial.

Negatives

• The TIGeR-PaC trial data readout is not expected until mid to late 2027, indicating a long development timeline.
• The IAG combination product candidate (gemcitabine via RenovoCath) is still under investigation and not approved for commercial sale.
• The company's ability to raise additional funding and manage cash resources is a stated risk.

Risks

• The risk that commercial opportunities for the TAMP technology may not lead to viable, revenue-generating operations.
• Circumstances that could adversely impact the ability to efficiently utilize cash resources or raise additional funding.
• The timing, progress, and potential results of preclinical studies and clinical trials, including the possibility that interim results may not be predictive of final outcomes.
• Regulatory authorities may disagree with data interpretation, research, or clinical development plans.
• The commercialization potential of product candidates, if approved.
• The ability to successfully manufacture and supply product candidates for clinical trials and commercial use.
• Potential for delays in regulatory filings and approvals.
• Competition from other product candidates and therapies in the industry.

Future Outlook

The company anticipates full enrollment in the TIGeR-PaC trial in the near term, with a final data readout expected in mid to late 2027. Commercialization efforts for RenovoCath are focused on increasing active customers and their utilization to drive revenue and reduce cash burn.

Management Comments

• The webinar will cover the exciting and rapidly evolving pancreatic cancer treatment landscape.
• Discussions will include RenovoRx's TAMP platform and its potential to deliver chemotherapies locally.
• Commercial launch of RenovoCath as a stand-alone device is showing promising results with growing revenues and a pathway for continued expansion.
• The company is focused on increasing active commercial cancer center customers and their utilization of TAMP and RenovoCath to drive revenue and reduce cash burn.

Industry Context

StockSavvy.ai notes that the focus on targeted oncology therapies and local drug delivery aligns with a significant trend in the pharmaceutical and biotech industry to improve treatment efficacy and reduce systemic toxicity. Pancreatic cancer remains a challenging disease with high unmet medical needs, making innovative approaches like RenovoRx's TAMP platform of particular interest.

Stakeholder Impact

• Shareholders: Potential positive impact from increased visibility of the TAMP platform and clinical trial progress, and continued commercialization of RenovoCath.
• Patients: Potential long-term benefit from the development of targeted therapies for pancreatic cancer.
• Healthcare Providers: Opportunity to learn about and potentially adopt RenovoRx's TAMP platform and RenovoCath device for patient treatment.

Next Steps

• Participate in the JonesTrading key opinion leader webinar on August 13, 2026.
• Continue the Phase III TIGeR-PaC clinical trial.
• Achieve full enrollment in the TIGeR-PaC trial in the near term.
• Expand the number of active commercial cancer center customers utilizing TAMP and RenovoCath.
• Generate final data readout for the TIGeR-PaC trial in mid to late 2027.

Key Dates

Recommendation

The filing indicates steady progress in clinical trials and commercialization, with positive developments like Orphan Drug Designation. However, the long timeline for trial data readout and the inherent risks in drug development warrant a 'hold' recommendation, pending further clinical and commercial milestones.

Keywords

pancreatic cancer, oncology therapies, drug-delivery device, TAMP platform, RenovoCath, clinical trial, gemcitabine, targeted therapy